Ceribell, Inc.
For the period ended Sep 30, 2025. Filed Nov 4, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 4, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Other Information
Item 5. Other Information.
Rule 10b5-1 Trading Plans
| Name | Action | Date | Trading Arrangement | Total Shares to be Sold | Expiration Date |
|---|---|---|---|---|---|
| Rule 10b5-1* | Non-Rule 10b5-1** | ||||
| Josef Parvizi, M.D., Ph.D.Director, Chief Medical Advisor, and Co-Founder | Adopt | August 18, 2025 | X | 275,000 | August 17, 2026 |
| David FoehrSenior Vice President, Finance | Terminate(1) | September 4, 2025 | X | 15,071 | March 10, 2026 |
| David FoehrSenior Vice President, Finance | Adopt | September 4, 2025 | X | 25,471 | September 4, 2026 |
| William W. BurkeDirector | Adopt | September 8, 2025 | X | 41,556 | July 7, 2026 |
| Xingjuan (Jane) ChaoPresident, Chief Executive Officer, Director, and Co-Founder | Adopt | September 12, 2025 | X | 531,000 | December 31, 2026 |
- Intended to satisfy the affirmative defense of Rule 10b5-1(c).
** Not intended to satisfy the affirmative defense of Rule 10b5-1(c).
(1)Dave Foehr’s trading plan, originally adopted on March 14, 2025, wasterminated on September 4, 2025. No trades were executed under the plan prior to its termination.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.